Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC
Molecular Therapy Oncology · 2026-09 · 34 (3) · 201247
DOI: 10.1016/j.omton.2026.201247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-09. Verfasst von Gabriella Antignani und 28 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunovirotherapy (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Biocenter Finland, Jane ja Aatos Erkon Säätiö.
Abstract (Originalsprache)
Immunotherapy has revolutionized cancer treatment, yet clinical success remains limited, with only a fraction of patients responding. Tumor heterogeneity and patient-specificity hinder response prediction, emphasizing the need for human-based models that accurately reproduce tumor-immune interactions. Conventional preclinical platforms, such as murine models, lack the human-specific HLA-TCR complexity, limiting their ability to accurately evaluate immunotherapy responses. To address this, we established a patient-specific pipeline for precision immunotherapy in renal cell carcinoma (RCC) and bladder cancer (BC). Tumor and adjacent tissues were used to generate patient-derived tumor organoids (PDTOs) and patient-derived cells (PDCs) for immunopeptidome profiling. Using our in-house microfluidic platform, PeptiCHIP, we identified tumor-associated HLA-I peptides as potential T cell targets. Their immunogenicity was evaluated using peptide-expanded, HLA-matched peripheral blood mononuclear cells (PBMCs), revealing peptides capable of inducing antigen-specific CD8+ T cell activation and cytotoxicity against the patient's tumor. This study integrates PDCs, immunopeptidomics, and functional immune assays to design and test personalized cancer immunotherapies. By recreating patient-specific tumor-immune interactions ex vivo, our platform enables the discovery of therapeutic targets, the evaluation of immune responses, and validation in a patient-specific context. This approach demonstrates the feasibility of bridging a major gap in translational immunotherapy research and supports the development of personalized cancer immunotherapy strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Immunovirotherapy (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
- Drug Research Program (DRP), Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
- Translational Immunology Research Program (TRIMM), University of Helsinki, Helsinki, Finland.
- Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.
- Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
- Institute for Molecular Medicine Finland (FIMM), Helsinki Institute for Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland.
Förderung
- European Research Council
- Biocenter Finland
- Jane ja Aatos Erkon Säätiö
- Finnish Cultural Foundation
- Medicinska Understödsföreningen Liv och Hälsa
- Erling-Perssons Stiftelse
- Magnus Ehrnroothin Säätiö
- Punainen Risti Veripalvelu
Zitieren
APA
Antignani, G., Feodoroff, M., Chiaro, J., Feola, S., Russo, S., Hamdan Hissaoui, F., Fusciello, M., D'Alessio, F., Bottega, P., Giannoula, Y., Sakalauskaite, M., Sandberg, J., Kosonen, M., Stigzelius, V., Luck, T. J., Ferrari, V., Ciampi, D., Haapala, M., Branca, R. M., …, & Cerullo, V. (2026). Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC. Molecular Therapy Oncology, 34(3), 201247. https://doi.org/10.1016/j.omton.2026.201247
Vancouver
Antignani G, Feodoroff M, Chiaro J, Feola S, Russo S, Hamdan Hissaoui F, et al. Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC. Molecular Therapy Oncology. 2026;34(3):201247. doi:10.1016/j.omton.2026.201247
BibTeX
@article{Antignani2026,
author = {Antignani, Gabriella and Feodoroff, Michaela and Chiaro, Jacopo and Feola, Sara and Russo, Salvatore and Hamdan Hissaoui, Firas and Fusciello, Manlio and D'Alessio, Federica and Bottega, Paolo and Giannoula, Yvonne and Sakalauskaite, Milda and Sandberg, Janita and Kosonen, Miska and Stigzelius, Virpi and Luck, Tamara J and Ferrari, Valentina and Ciampi, Daniele and Haapala, Markus and Branca, Rui Mamede and Partanen, Jukka and Koskela, Satu and Rescigno, Maria and Sikanen, Tiina and Lehtiö, Janne and Ndika, Joseph and Kari, Otto K and Pietiäinen, Vilja M and Grönholm, Mikaela and Cerullo, Vincenzo},
title = {Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {3},
pages = {201247},
doi = {10.1016/j.omton.2026.201247}
}
EUVIMED